News
IMMP
2.130
+1.43%
0.030
*Immutep Target Price Cut 7.1% to A$1.05/Share by Wilsons>IMM.AU
Dow Jones · 2d ago
Immutep Advances Cancer Trial with FDA Approval
TipRanks · 3d ago
Immutep gains positive feedback from FDA on phase 3 NSCLC candidate program
Immutep gains positive feedback from FDA on phase 3 NSCLC candidate program. The U.S. FDA has given Immutep positive feedback on its first-line lung cancer treatment eftilagimod alfa. The phase 3 TACTI-004 trial will enroll 750 patients.
Seeking Alpha · 4d ago
Immutep Announces Successful Meeting With FDA On Phase III Design In Non-Small Cell Lung Cancer; TACTI-004 Registrational Trial Will Enrol ~750 Patients Regardless Of PD-L1 Expression In Order To Address The Entire 1l NSCLC Market Eligible For anti-PD-1 Therapy
Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA and chemotherapy in first-line non-small cell lung cancer. TACTi-004 registrational trial will enrol ~750 patients regardless of PD-L1 expression. The planned trial will address the entire 1L NSCLC market eligible for anti-PD-1 therapy.
Benzinga · 4d ago
IMMUTEP LTD: TACTI-004 REGISTRATIONAL TRIAL WILL ENROL ABOUT 750 PATIENTS REGARDLESS OF PD-L1 EXPRESSION
Reuters · 4d ago
Weekly Report: what happened at IMMP last week (0715-0719)?
Weekly Report · 4d ago
Jefferies Remains a Buy on Immutep Ltd (PRRUF)
TipRanks · 07/18 12:17
Immutep Receives Regulatory Clearance For Phase I Study Of First-In-Class LAG-3 Agonist Antibody Designed To Treat Autoimmune Diseases
Study expected to enrol first participants during Q3 CY2024. IMP761 is the world's first therapeutic LAG-3 agonist antibody. Immutep is developing novel immunotherapies for cancer and autoimmune diseases. The company has received regulatory clearance to initiate the first-in-human Phase I study.
Benzinga · 07/17 12:07
Analysts’ Top Healthcare Picks: UnitedHealth (UNH), Immutep (IMMP)
Goldman Sachs analyst Nathan Rich maintained a Buy rating on UnitedHealth yesterday. Immutep has an analyst consensus of Strong Buy, with a 322.9% upside from current levels. The company's shares closed last week at $554.70. 2 analysts have also maintained Buy ratings on the Healthcare sector.
TipRanks · 07/17 01:10
Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs
Seeking Alpha · 07/15 17:54
Weekly Report: what happened at IMMP last week (0708-0712)?
Weekly Report · 07/15 10:11
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Immutep (IMMP)
TipRanks · 07/15 09:50
Buy Rating Affirmed: Immutep’s Efti Shows Promising Results in HNSCC Therapy
TipRanks · 07/15 05:35
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
ASP Isotopes Inc. Shares fell 9.2% to $3.2308 on Friday. The company announced pricing of a $30 million public offering of 12 million shares at $2.50 per share. Vicinity Motor Corp. Shares jumped 133.2%. Other stocks moving in today's mid-day session.
Benzinga · 07/12 17:15
Market-Moving News for July 12th
Zapp Electric Vehicles shares trading higher. Fastenal shares are trading higher following better-than-expected Q2 earnings. Immutep shares are also trading higher after the company announced positive results in a cancer trial. Zapp Electric Vehicle enters into a deal to start production of the i300 electric urban motorcycle in India.
Benzinga · 07/12 12:37
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Crown LNG stock is rocketing almost 154% after completing a business combination. Crown LNG is one of 10 top pre-market stock movers to watch on Friday morning. The biggest pre- market stocks to watch are mergers, clinical trial data, public offerings and more.
Investorplace · 07/12 11:41
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Immutep Limited released results from a Phase 2b trial of eftilagimod alfa in combination with Merck's Keytruda. The drug is being tested for treatment of squamous cell carcinoma patients with negative PD-L1 expression.
Benzinga · 07/12 11:39
Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Telefonaktiebolaget LM Ericsson shares rose sharply in today's pre-market trading. The company reported better-than-expected second-quarter sales and issued guidance. Sentage Holdings Inc. Shares rose 85.6% to $4.27 after surging 85% on Thursday.
Benzinga · 07/12 09:35
Biggest stock movers today: TSLA, ERIC, and more
Biggest stock movers: Ericsson's stock price rose more than 7% following Q2 results. Immutep shares surged over 20% after announcing positive results from a cancer trial. Tesla, Inc. (TSLA) was downgraded from Neutral to Sell by UBS on Friday.
Seeking Alpha · 07/12 09:19
Immutep gains after positive results from cancer trial
Seeking Alpha · 07/12 08:59
More
Webull provides a variety of real-time IMMP stock news. You can receive the latest news about Immutep through multiple platforms. This information may help you make smarter investment decisions.
About IMMP
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.